In brief: KabaFusion gets new investor, Philips closes recall portal, ABN set to expire

LEXINGTON, Mass. – KabaFusion has announced that Novo Holdings has exited its investment and Nautic Partners has completed its growth investment in the company. 

KabaFusion says its clinician-led management team remains a significant investor and will continue to lead the company. 

“We are thrilled to partner with Nautic, whose deep health care expertise and collaborative approach will help accelerate our growth and expand access to high-quality infusion care,” said Dr. Sohail Masood, CEO and founder KabaFusion. “Nautic is a natural partner for us, sharing our commitment to delivering exceptional clinical outcomes through a patient-first model, and together we look forward to enhancing the experience for the patients and providers we serve.” 

Today, KabaFusion is licensed to serve patients in 45 states through its expansive network of 33 infusion pharmacies and 21 ambulatory infusion suites. 

This new growth partnership with Nautic will enable KabaFusion to accelerate and further expand its mission to serve patients, health care practitioners and payers nationwide with the highest quality home infusion services and unmatched clinical excellence, the company says. 

“We have long admired Dr. Masood and the KabaFusion team, who have earned their position as a distinguished leader in home infusion through differentiated clinical expertise and an unwavering patient-first culture,” said Joe Anderson, managing director at Nautic Partners. “We are excited to partner with Dr. Masood and his team to support continued innovation and expand access to the highest quality of care.” 

Nautic Partners is a middle-market private equity firm based in Providence, R.I., that focuses on investments in three sectors: health care, industrial and services. It has completed more than 160 platform transactions over its 38-year history.   

Other recent KabaFusion news: 

• KabaFusion has closed on the acquisition of six locations from Coram that will serve as pharmacies and ambulatory infusion suites. 
• Memorial Hermann Health System has established a services agreement with KabaFusion to provide home infusion therapy for patients with chronic conditions and for those who need intravenous immunoglobulin (IVIG) treatment.   

Philips closes patient portal for recalled devices 

ANDOVER, Mass. – Philips says it has completed actionable registrations across sleep therapy and ventilator devices and is closing the U.S. Patient Portal related to its recall as of Jan. 1, 2026. 

In a Jan. 1 post to a website dedicated to recall information, Philips stated: 

Our progress in completing actionable registrations across sleep therapy and ventilation devices marks an important milestone in the June 2021 recall.  

As a result of this progress, the US Patient Portal for affected CPAP and BiPAP devices is no longer available as of January 1, 2026.  

We will continue to prioritize remediation of registered sleep and respiratory care devices and will also continue to accept returned affected devices at no cost.  

If you have questions on the closure of affected device registration or the US Patient Portal closure, please contact CPAPRecallClosure@philips.com and provide your name, phone number, shipping address (we cannot accept P.O. boxes), affected device serial number and your specific question. Failure to provide this information could lead to a delay in response. 

Related coverage: 

• Philips consent decree outlined 
• Philips settles additional lawsuits 
• Philips has ‘finality’ 

McKesson fully exits European market 

IRVING, Texas – McKesson has announced that it has sold its retail and distribution businesses in Norway to NorgesGruppen, a privately-owned retail group. McKesson previously announced that it planned to divest Norway, which is included in its Other segment. The transaction represents the final step in the company’s commitment to fully exit its European operations. The move allows the company to focus strategy and capital allocation on expanding and accelerating its growth platforms within its Oncology and Multispecialty and Biopharma Services segments. McKesson also plans to spin off its Medical-Surgical segment. The company also recently announced that its board of directorshas declared a regular dividend of 82 cents per share of common stock payable on April 1, 2026, to shareholders of record on March 2, 2026. 

CMS working on updated advance beneficiary form 

YARMOUTH, Maine – The current advance beneficiary form of noncoverage, ABN Form CMS-R-131, is scheduled to expire on Jan. 31, 2026, according to an update posted by Noridian Healthcare Solutions, the DME MAC for Jurisdiction D. The contractor says the Centers for Medicare & Medicaid Services (CMS) is actively developing an updated version of the form. Once the new form is finalized, Noridian and CMS will make an announcement on their websites, along with any related implementation guidance. Noridian says durable medical equipment (DME) providers should continue using the existing ABN format until further instructions are issued. The contractor says to monitor the following websites for updates: 

• https://www.cms.gov/medicare/forms-notices/beneficiary-notices-initiative 
• https://med.noridianmedicare.com/web/jddme/topics/abn 

An ABN is a written notice a provider gives to a Medicare beneficiary before providing an item and/or service. It must be issued when the health care provider (including independent laboratories, physicians, practitioners and providers) believes that Medicare may not pay for an item or service which is expected to be denied by Medicare based on certain statutory exclusions. 

HQAA names new executive director 

WATERLOO, Iowa – The Healthcare Quality Association on Accreditation (HQAA) has announced that Executive Director Rhonda Pearce is retiring and will be replaced by Craig Douglas. Pearce joined HQAA in 2005 and has been the organization’s executive director since 2016. During her leadership, she further developed and modernized HQAA’s programs and contributed time and resources to better the surrounding community. “We would like to thank Rhonda for her years of dedicated service and commitment to HQAA,” said Carol Laumer, chair of the board of directors. “Her leadership, commitment and vision have certainly positioned us for continued success.” Following a comprehensive search process, HQAA’s board selected Douglas, formerly vice president of payer relations and senior vice president of HME, respiratory and wellness for VGM & Associates, as its next executive director. He brings 27 years of experience in the DMEPOS industry. “I’m honored to build on the strong foundation established by Rhonda,” Douglas said. “I look forward to honoring what she has accomplished here, and continuing to advance HQAA’s mission of assisting reputable, high quality health care providers.” Pearce will continue to support the transition over the coming weeks, ensuring a smooth transition of responsibilities. 

VGM promotes Boone Lockard 

WATERLOO, Iowa – VGM & Associates has promoted Boone Lockard to vice president of HME, Respiratory & Wellness. In this new position, he will focus on creating a long-term plan to support members as the face industry challenges and implement strategies for business growth. “VGM is dedicated to providing innovative solutions that help our members stay competitive,” said Lindy Tentinger, president of VGM & Associates. “Boone’s expertise gives us a significant advantage as we guide our members and show them a clear roadmap to success in an ever-evolving industry.” Lockard joined VGM in 2022 and most recently served as VP of Clinical Services. He has significant experience as a respiratory therapist, along with expertise in clinical work, operations, billing, management, and sales within the HME industry. This well-rounded background has been vital in supporting members, VGM says. “I’m grateful to work with the team at VGM & Associates that supports the HME industry as a whole,” Lockard said. “HME is essential for so many, and our work makes a difference. I look forward to continuing to help members deliver excellent care to patients in my expanded role.” 

• Related: During an episode of the HME News in 10 podcast, Boone Lockard called value-based care the “biggest ticket item” that HME providers need to buy into in the next few years.   

Senseonics to enter EU markets with Eversense 365 CGM system 

GERMANTOWN, Md. - Senseonics Holdings has announced CE Mark approval for the Eversense 365 CGM system, paying the way for the company to enter the German, Italian, Spanish and Swedish markets in the coming months. “European approval for Eversense 365 represents the latest achievement in our long-term growth strategy for Senseonics and expands our total addressable market by over 30 million patients living with diabetes in the EU,” said Tim Goodnow, PhD, president and CEO of Senseonics. “As we take full ownership of all commercial activities for Eversense 365, we expect our expansion in Europe to contribute to top-line revenue growth, while offering a single year-long CGM solution to glucose monitoring. 2026 will be an exciting year as we drive commercial progress in the U.S. and Europe, expect the impact of the integration with Sequel’s twiist Automated Insulin Delivery (AID) System in the U.S., and simultaneously await planned completion of the Gemini trial in the second half of the year.” The Eversense 365, billed as the world’s first and only one-year CGM, was approved by the U.S. Food and Drug Administration (FDA) in September of 2024 and launched in the country one month later.  

REMSleep secures coding approval for DeltaWave 

BLACKSHEAR, Ga. - REMSleep Holdings has announced that it has received HCPCS approval from the Pricing, Data Analysis and Coding (PDAC) contractor for its DeltaWave nasal pillow system. This approval allows durable medical equipment (DME) providers to bill Medicare and private insurance payers for all configurations of the DeltaWave system. “This marks a critical milestone for our DME partners who now have everything they need, the expanded FDA clearance, HCPCS codes for all configurations, and a fully stocked inventory,” said Thomas Wood, CEO and founder of REMSleep. “We are excited to proceed with the full commercial launch of DeltaWave, offering a solution that meets the diverse needs of the sleep therapy market.” Earlier this month, REMSleep announced expanded 510(k) clearance from the U.S. Food and Drug Administration, significantly broadening DeltaWave’s indicated use beyond home-based CPAP therapy to include institutional settings and a wider range of patient populations.  With regulatory and reimbursement barriers now cleared, the company is activating a three-channel strategy that includes reaching out to DME providers to target the 20% to 30% of CPAP patients who fail their initial mask. “We have transitioned from a soft launch with a limited FDA clearance to being fully prepared for national distribution,” Wood said. “This is a significant leap toward providing a complete solution for our customers.”